Peer-Reviewed Publication
UNIVERSITY OF UTAH HEALTH
IMAGE:
TORRI METZ, MD, VICE CHAIR OF RESEARCH OF OBSTETRICS AND GYNECOLOGY AT UNIVERSITY OF UTAH HEALTH, WHO CO-LED THE NATIONWIDE STUDY.
CREDIT: CHARLIE EHLERT / UNIVERSITY OF UTAH HEALTH
Nearly one in 10 people who get COVID while pregnant will go on to develop long COVID, a report publishing July 11th in Obstetrics & Gynecology has found.
“It was surprising to me that the prevalence was that high,” says Torri Metz, MD, vice chair of research of obstetrics and gynecology at University of Utah Health, who co-led the nationwide study. “This is something that does continue to affect otherwise reasonably healthy and young populations.”
Intersecting risks
Prior research had shown that COVID affects pregnant people in uniquely risky ways. A COVID infection during pregnancy is more likely to lead to hospitalization or death, compared to an infection outside of pregnancy. COVID also increases the risk of pregnancy-related complications such as preterm birth or stillbirth. But until this study, the risk to pregnant people of developing long COVID was unknown.
The researchers enrolled more than 1500 people nationwide who had been sick with COVID for the first time while pregnant, and assessed self-reported long COVID symptoms at least six months after infection. As part of the National Institutes of Health RECOVER project, a massive nationwide collaboration to understand and treat long COVID, the large size of the study established solid associations and provided a picture of risk that was accurate for pregnant people across demographic groups.
The researchers found that 9.3% of people who contracted COVID during pregnancy went on to experience long-term symptoms. Some of the most common long COVID symptoms participants experienced were fatigue, gastrointestinal issues, and feeling drained or exhausted by routine activities.
“This is a critical study as pregnancy and the post-partum period are one of the most vulnerable times in an individual’s life,” said David Goff, M.D., Ph.D., division director for the Division of Cardiovascular Sciences at the NIH’s National Heart, Lung, and Blood Institute. “By better understanding how individual characteristics interact with SARS-CoV-2 infection during pregnancy and lead to an increased risk of long COVID, this study yields important insights to potentially develop targeted interventions for this population.”
Because the symptoms of long COVID can overlap with the symptoms of pregnancy itself, Metz says that it’s especially important for obstetricians to be vigilant for them. “I doubt most obstetric clinicians are as aware of long COVID as perhaps we should be,” Metz says. “But people are having these symptoms, and we need to make sure that we’re not forgetting that these could be long-term manifestations of their SARS-CoV-2 infection.”
To ensure that the reported long COVID symptoms weren’t symptoms of pregnancy, the researchers did a secondary analysis that was restricted to people who reported symptoms more than 12 weeks after giving birth. The estimated risk of long COVID remained similar, confirming the initial findings.
Metz says that while the rate of long COVID observed was surprisingly high, it could underestimate the actual risk of long COVID for pregnant people. On average, people reported whether or not they had symptoms of long COVID 10 months after their initial infection, which means that the study could have missed people whose symptoms resolved earlier.
Several factors were associated with an increased risk of long COVID. People with anxiety or depression prior to their infection, as well as people with obesity, were more likely to experience lasting symptoms. Self-reported financial hardship was also associated with higher rates of long COVID, although the study could not determine whether financial difficulties were a cause or a consequence of extended symptoms.
“Our results highlight that people who were pregnant when they got COVID may have significant long-term symptoms after pregnancy, like fatigue even after simple activities that they did before the infection,” says senior author Vanessa Jacoby, MD, MAS, director of the Clinical and Translational Science Institute at UCSF, and a professor of obstetrics, gynecology, and reproductive sciences as well as Associate Vice Chancellor for Clinical Research. “We encourage people to speak with their healthcare provider about persistent symptoms to connect with appropriate support and care,” she says.
A continued concern
Previous estimates of long COVID rates following infection in the general population range from 10% to over 20%, putting the researchers’ results on the lower end of the risk spectrum. Metz says that this could be because pregnant people’s immune systems tend to react less strongly to infection. This puts pregnant people at higher risk of severe symptoms during the infection, but may put them at lower risk of long-term organ damage that can lead to persistent symptoms. Pregnant people tend to be overall younger and healthier than other populations, which could also contribute to the difference.
But the high prevalence of long COVID, including in pregnant populations, emphasizes that health practitioners should keep an eye out for its symptoms, Metz says. “We need to have this on our radar as we’re seeing patients. It’s something we really don’t want to miss. And we want to get people referred to appropriate specialists who treat long COVID.”
U of U Health’s Long COVID Clinic specializes in caring for patients with prolonged symptoms of COVID-19. Learn more about the clinic here.
About RECOVER: The National Institutes of Health Researching COVID to Enhance Recovery (NIH RECOVER) Initiative brings together clinicians, scientists, caregivers, patients, and community members to understand, diagnose, and treat long COVID. RECOVER has created one of the largest and most diverse groups of Long COVID study participants in the world. In addition, RECOVER clinical trials are testing potential interventions across five symptom focus areas. For more information, please visit recoverCOVID.org.
This research was published as “Post–Acute Sequelae of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) After Infection During Pregnancy” in Obstetrics and Gynecology.
The study was funded by the National Institutes of Health (NIH) Agreements OTA OT2HL161847, OT2HL161841 and OT2HL156812 as part of the Researching COVID to Enhance Recovery (RECOVER) Research Initiative.
The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
JOURNAL
Obstetrics and Gynecology
DOI
10.1097/AOG.0000000000005670
METHOD OF RESEARCH
Observational study
SUBJECT OF RESEARCH
People
ARTICLE TITLE
Post–Acute Sequelae of Severe Acute Respi- ratory Syndrome Coronavirus 2 (SAR- S-CoV-2) After Infection During Pregnancy
ARTICLE PUBLICATION DATE
11-Jul-2024
COI STATEMENT
Torri D. Metz is the site PI for a Pfizer study of Paxlovid in pregnancy and was the site PI for a Pfizer study of COVID-19 vaccination in pregnancy. She has received UpToDate royalties for two topics on trial of labor after cesarean. Carmen J. Beamon disclosed receiving payments from Wellcare of North Carolina. Ann Chang’s institution received payment from New York University for her efforts on this study. Kelly S. Gibson disclosed that her institution received funding from the NICHD, NHLBI, and Materna. Rachel Hess received payment from Astellas Pharmaceuticals. M. Camile Hoffman disclosed her institution received payment for her expert testimony for one medicolegal trial from Wheeler, Trigg, and Associates (a defense attorneys firm). Her institution also received payment for a disease state presentation on postpartum depression and zuranolone from SAGE/Biogen. Brenna L. Hughes disclosed receiving payments from UpToDate and Moderna. Stuart Katz disclosed payments for providing expert testimony for Venable LLP. Jennifer Hadlock has received funding (paid to institution) for retrospective studies of COVID-19 from Pfizer, Novartis, Janssen, and Gilead. Grace A. McComsey served as an advisor for Gilead and ViiVGlaxoSmithKline. Patrick Ramsey disclosed receiving royalties from UpToDate. His institution was paid by the Texas Collaborative for Healthy Mothers and Babies (TCHMB)— Texas PQC for part of his efforts. Daniel W. Skupski reports receiving payments from Organon, Inc and Cooper Surgical. Alan T.N. Tita disclosed money paid to his institution from Pfizer for his efforts in this study. Andrea Foulkes disclosed receiving past payments from Round Table, Inc. The other authors did not report any potential conflicts of interest.
Leave a Reply